Application of mesenchymal stem cells and extracellular vesicles in infectious treatment
- 作者: Yudintceva N.M.1, Shevtsov M.A.1, Khotin M.G.1, Vinogradova T.I.2, Muraviov A.N.2,3, Remezova A.N.2, Mikhailova N.A.1
-
隶属关系:
- Institute of Cytology of the Russian Academy of Sciences (RAS)
- Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of Russian Federation
- Private University «Saint-Petersburg Medico-Social Institute»
- 期: 卷 20, 编号 6 (2022)
- 页面: 16-24
- 栏目: Reviews
- URL: https://journals.eco-vector.com/1728-2918/article/view/321278
- DOI: https://doi.org/10.29296/24999490-2022-06-03
- ID: 321278
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Mesenchymal stem cells (MSCs) are attractive in various fields of regenerative medicine due to their therapeutic potential and complex unique properties. Basic stem cell research and the global COVID-19 pandemic have given impetus to the development of cell therapy for infectious diseases.
The aim of this review is to systematize scientific data on the use of MSCs and their extracellular vesicles (MSC-EVs) in the complex treatment of infectious diseases.
Material and methods: an analysis of the main foreign sources in the databases of NCBI, Elsevier, PubMed/Medline for 2004–2022 was carried out.
Results. Application of MSCs and MSC-EVs in the treatment of infectious diseases has an immunomodulatory, anti-inflammatory and antibacterial effect, and also promotes the restoration of the epithelium and stimulates tissue regeneration. The use of MSC-EVs is a promising cell-free treatment strategy that allows solving the problems associated with the safety of cell therapy and increasing its effectiveness.
Conclusion. In this review, experimental data and clinical trials based on MSCs and MSC-EVs for the treatment of infectious diseases are presented. MSCs and MSC-EVs can be a promising tool for the treatment of various infectious diseases in combination with antiviral drugs. Using of MSC-EVs instead of cells is a more promising strategy for cell-free treatment, since it allows solving various problems of cell therapy.
全文:
作者简介
Natalia Yudintceva
Institute of Cytology of the Russian Academy of Sciences (RAS)
编辑信件的主要联系方式.
Email: yudintceva@mail.ru
ORCID iD: 0000-0002-7357-1571
Senior researcher. PhD of biological sciences
俄罗斯联邦, Tikhoretsky ave., 4, St. Petersburg, 194064Maxim Shevtsov
Institute of Cytology of the Russian Academy of Sciences (RAS)
Email: shevtsov-max@mail.ru
ORCID iD: 0000-0002-8539-2239
Leader scientific worker. Doctor of biological sciences.
俄罗斯联邦, Tikhoretsky ave., 4, St. Petersburg, 194064Mihail Khotin
Institute of Cytology of the Russian Academy of Sciences (RAS)
Email: h_mg@mail.ru
ORCID iD: 0000-0002-8293-6368
Scientific researcher. PhD of biological sciences.
俄罗斯联邦, Tikhoretsky ave., 4, St. Petersburg, 194064Tatiana Vinogradova
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of Russian Federation
Email: vinogradova@spbniif.ru
ORCID iD: 0000-0002-5234-349X
Expert scientific worker. Doctor of medical sciences, Professor.
俄罗斯联邦, Ligovsky ave., 2–4, St. Petersburg, 191036Alexandr Muraviov
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of Russian Federation; Private University «Saint-Petersburg Medico-Social Institute»
Email: urolog5@gmail.com
ORCID iD: 0000-0002-6974-5305
Leader scientific worker. PhD of medical sciences.
俄罗斯联邦, Ligovsky ave., 2–4, St. Petersburg, 191036; Kondratievsky ave., 72, lit. А, St. Petersburg, 195271Anna Remezova
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of Russian Federation
Email: ani199520@yandex.ru
ORCID iD: 0000-0001-8145-4159
junior researcher. PhD student.
俄罗斯联邦, Ligovsky ave., 2–4, St. Petersburg, 191036Natalia Mikhailova
Institute of Cytology of the Russian Academy of Sciences (RAS)
Email: natmik@mail.ru
ORCID iD: 0000-0002-8888-0190
Leader scientific worker. Doctor of biological sciences.
俄罗斯联邦, Tikhoretsky ave., 4, St. Petersburg, 194064参考
补充文件
